European journal of drug metabolism and pharmacokinetics

Modeling how psilocybin from magic mushrooms acts in the body and brain to treat hard-to-treat depression

Psychedelic Science Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Psilocybin may exert antidepressant effects through serotonin 2A receptor activation.

  • Psilocybin converts to psilocin, which is responsible for its psychedelic properties.
  • Rapid and sustained antidepressant effects have been observed in treatment-resistant depression.
  • The optimal dose for balancing therapeutic benefits and safety is currently unclear.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the psychedelic science brief

issue #53
One psilocybin session held antidepressant effects for 52 weeks in a new follow-up study
2 weeks ago7 studies
issue #52
Psilocybin didn't create disorder in the brain — it created a different kind of order
3 weeks ago7 studies
issue #51
Psilocybin worked for treatment-resistant depression in real Swiss clinics — not just controlled trials
4 weeks ago7 studies
issue #50
Psilocybin beat placebo on depression scores in an NHS trial — by a lot
5 weeks ago7 studies
issue #49
Psilocybin stays active in neurons long after it leaves the bloodstream — here's what that means
6 weeks ago7 studies
issue #48
Psychedelics during adolescence reshaped adult social behavior in rats — here's the circuit
7 weeks ago7 studies
issue #47
Psilocybin rewired prefrontal circuits in mice — but only for one specific type of cognitive failure
8 weeks ago7 studies
issue #46
Psilocybin cut two specific brain chemicals in depressed patients — here's what that means
9 weeks ago7 studies
issue #44
Psilocybin rewires brain feedback circuits for weeks after a single dose, new evidence shows
10 weeks ago7 studies
issue #43
A pill form of ketamine cut dissociation to near-zero vs. nasal spray's 29.6-point spike — but missed its main antidepressant target
11 weeks ago7 studies
explore the archive
See more issues from the psychedelic science brief